cas 1255527-73-1|| where to buy methyl 3-methyl-1H-indole-4-carboxylate

Название продукции:methyl 3-methyl-1H-indole-4-carboxylate

IUPAC Name:methyl 3-methyl-1H-indole-4-carboxylate

: CAS：1255527-73-1; Молекулярная формула：C11H11NO2; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1255527-73-1 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:1255527-73-1; Молекулярная формула:C11H11NO2; Точка плавления:-; Smiles-код:COC(=O)C1=CC=CC2=C1C(C)=CN2; Плотность:

: Номер в каталоге:CM1075215; Молекулярная масса:189.21; Точка кипения:; Номер Mdl:; Хранение:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Bexicaserin; Longboard announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The analysis showed that bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures across the DEE study population. Longboard will rapidly advance bexicaserin's global Phase 3 trial.